INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1701, 28955, 'Leflunomide', 'Tuberculosis', 'Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment.  Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1702, 832, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1703, 978, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1704, 979, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1705, 1149, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1706, 1150, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1707, 1151, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1708, 7176, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1709, 12066, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1710, 13039, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1711, 21678, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1712, 21679, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1713, 25621, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1714, 25622, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1715, 28954, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1716, 28955, 'Leflunomide', 'Hypertension', 'Hypertension was reported as an adverse reaction in patients on leflunomide.  Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1717, 6419, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1718, 20659, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1719, 20660, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1720, 20661, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1721, 20662, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1722, 20903, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1723, 20904, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1724, 20905, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1725, 29800, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1726, 30582, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1727, 30583, 'Antilymphocyte immunoglobulin (horse)', 'IMMUNE SUPPRESSION', 'Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine).  Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient.  There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists.  If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1728, 6419, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1729, 20659, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1730, 20660, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1731, 20661, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1732, 20662, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1733, 20903, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1734, 20904, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1735, 20905, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1736, 29800, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1737, 30582, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1738, 30583, 'Antilymphocyte immunoglobulin (horse)', 'Liver Failure', 'The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine).  It is recommended to evaluate these tests closely in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1739, 0, 'Lemborexant', 'Alcoholism', 'Patients treated with lemborexant should not consume alcohol as it can increase drowsiness and also the incidence of adverse effects.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1740, 0, 'Lemborexant', 'Pulmonary Disease, Chronic Obstructive', 'Lemborexant has not been studied in patients with moderate to severe obstructive sleep apnea (OSA) or in patients with chronic obstructive pulmonary disease.  Caution is advised if prescribing to patients with compromised respiratory function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1741, 0, 'Lemborexant', 'Depressive Disorder', 'Worsening of depression and suicidal thoughts and actions have been reported with the use of lemborexant.  Caution is advised in patients with depression.  Protective measures may be required in patients with suicidal tendencies, including prescription of the lowest number of tablets at one time.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1742, 0, 'Lemborexant', 'Liver Failure', 'Lemborexant has not been studied in patients with severe liver dysfunction (Child-Pugh Class C).  Its use is not recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1743, 6227, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1744, 20747, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1745, 20748, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1746, 21694, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1747, 21695, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1748, 25971, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1749, 25972, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1750, 25973, 'Lenalidomide', 'Kidney Diseases', 'Lenalidomide is primarily excreted unchanged by the kidney.  Adjustments to the starting dose are recommended in patients with moderate (CrCl 30-60 mL/min) or severe renal impairment (<30 mL/min), and in patients on dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1751, 6227, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1752, 20747, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1753, 20748, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1754, 21694, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1755, 21695, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1756, 25971, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1757, 25972, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1758, 25973, 'Lenalidomide', 'Thromboembolism', 'Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboses are increased in patients using lenalidomide.  Patients with known risk factors such as prior thrombosis, may be at greater risk and actions should be taken to minimize all other modifiable risk factors (e.g., smoking, hyperlipidemia, hypertension).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1759, 6227, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1760, 20747, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1761, 20748, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1762, 21694, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1763, 21695, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1764, 25971, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1765, 25972, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1766, 25973, 'Lenalidomide', 'Anemia', 'Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia.  Patients with these preexisting conditions should be monitored carefully.  Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1767, 314, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1768, 4048, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1769, 4777, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1770, 7215, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1771, 12699, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1772, 18918, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1773, 21721, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1774, 21723, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1775, 32443, 'Letrozole', 'Liver Diseases', 'Letrozole is extensively metabolized by the liver.  The pharmacokinetic disposition of letrozole has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with letrozole should be administered cautiously to patients with severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1776, 314, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1777, 4048, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1778, 4777, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1779, 7215, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1780, 12699, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1781, 18918, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1782, 21721, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1783, 21723, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1784, 32443, 'Letrozole', 'Hypercholesterolemia', 'In an adjuvant clinical trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.  CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.  Also in the adjuvant setting, an increase of >=1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., <=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840 (3.2%).  Caution is recommended when prescribing letrozole to these patients.  Consideration should be given to monitoring serum cholesterol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1785, 314, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1786, 4048, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1787, 4777, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1788, 7215, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1789, 12699, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1790, 18918, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1791, 21721, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1792, 21723, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1793, 32443, 'Letrozole', 'Osteoporosis', 'Use of letrozole tablets may cause decreases in bone mineral density (BMD).  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with letrozole.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1794, 21700, 'Lenvatinib', 'Thromboembolism', 'In clinical trials, arterial thromboembolic events were reported in patients treated with lenvatinib.  It is recommended to discontinue lenvatinib following an arterial thrombotic event.  Care should be exercised when resuming lenvatinib after an arterial thromboembolic event as its safety has not been established and its use has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1795, 21701, 'Lenvatinib', 'Thromboembolism', 'In clinical trials, arterial thromboembolic events were reported in patients treated with lenvatinib.  It is recommended to discontinue lenvatinib following an arterial thrombotic event.  Care should be exercised when resuming lenvatinib after an arterial thromboembolic event as its safety has not been established and its use has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1796, 21700, 'Lenvatinib', 'Hemorrhage', 'Hemorrhagic events, including fatal hemorrhagic events have been reported with the use of lenvatinib.  It is recommended to withhold treatment and to either resume at a reduced dose or discontinue treatment depending on the severity and persistence of hemorrhage.  Discontinue therapy in patients who experience severe or fatal hemorrhagic events.  Prior to initiating treatment, consider the risk of severe or fatal hemorrhage associated with tumor invasion/infiltration of major blood vessels (e.g.  carotid artery).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1797, 21701, 'Lenvatinib', 'Hemorrhage', 'Hemorrhagic events, including fatal hemorrhagic events have been reported with the use of lenvatinib.  It is recommended to withhold treatment and to either resume at a reduced dose or discontinue treatment depending on the severity and persistence of hemorrhage.  Discontinue therapy in patients who experience severe or fatal hemorrhagic events.  Prior to initiating treatment, consider the risk of severe or fatal hemorrhage associated with tumor invasion/infiltration of major blood vessels (e.g.  carotid artery).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1798, 21700, 'Lenvatinib', 'Heart Failure', 'Cardiac dysfunctions, defined as decreased left or right ventricular function, cardiac failure, or pulmonary edema have been reported with the use of lenvatinib.  It is recommended to monitor patients for clinical symptoms or signs of cardiac decompensation.  Withhold lenvatinib therapy for development of Grade 3 cardiac dysfunction until improved and either resume at a reduced dose or discontinue its use depending on the severity and persistence of cardiac dysfunction.  Discontinue lenvatinib for Grade 4 cardiac dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1799, 21701, 'Lenvatinib', 'Heart Failure', 'Cardiac dysfunctions, defined as decreased left or right ventricular function, cardiac failure, or pulmonary edema have been reported with the use of lenvatinib.  It is recommended to monitor patients for clinical symptoms or signs of cardiac decompensation.  Withhold lenvatinib therapy for development of Grade 3 cardiac dysfunction until improved and either resume at a reduced dose or discontinue its use depending on the severity and persistence of cardiac dysfunction.  Discontinue lenvatinib for Grade 4 cardiac dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1800, 21700, 'Lenvatinib', 'Diarrhea', 'Cases of diarrhea have been reported with the use of lenvatinib, sometimes leading to interruption of therapy.  It is recommended to initiate prompt medical management for the development of diarrhea and to monitor for dehydration.  It might be necessary to interrupt treatment with lenvatinib or resume at a reduced dose or permanently discontinue treatment with lenvatinib if severe or fatal diarrhea persists despite medical management.  Care and close monitoring is recommended when using this agent in patients presenting diarrhea or at risk of developing diarrhea.', '2', '', 'DDInter', 0);
